日本がん治療薬市場模、シェア、競争環境、動向分析レポート：用途別（肺がん、血液がん、大腸がん、前立腺がん、乳がん、子宮頸がん、膠芽腫、頭頸部がん、悪性髄膜腫、中皮腫、黒色腫、その他）、治療薬別（化学療法、 治療法別（化学療法、標的療法、免疫療法、ホルモン療法、その他）、売れ筋医薬品別（レブリミド、アバスチン、ハーセプチン、リツキサン、オプジーボ、グリベック、ベルケイド、インブルビカ、イブランス、ザイティガ、アリムタ、エクタンディ、タルセバ、ペルジェタ、テモダール、その他）、エンドユーザー別（病院、専門クリニック、がん・放射線治療センター）： 2025-2033 年の機会分析と産業予測

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of Covid-19 on Japan Cancer Drug Market

4. Executive Summary

5. Japan Cancer Drug Market Outlook, 2025 - 2033

6.1. Market Size & Forecast

6.2. By Application

6.2.1. Lung Cancer

6.2.2.Blood Cancer

6.2.3.Colorectal Cancer

6.2.4.Prostate Cancer

6.2.5.Breast Cancer

6.2.6.Cervical Cancer

6.2.7.Glioblastoma

6.2.8.Head & Neck Cancer

6.2.9.Malignant Meningioma

6.2.10. Mesothelioma

6.2.11. Melanoma

6.2.12. Others

6.3. By Therapeutics

6.3.1.Chemotherapy

6.3.2.Targeted Therapy

6.3.3.Immunotherapy

6.3.4.Hormonal Therapy

6.3.5.Other

6.4. By Top Selling Drugs

6.4.1.Revlimid

6.4.2.Avastin

6.4.3.Herceptin

6.4.4.Rituxan

6.4.5.Opdivo

6.4.6.Gleevec

6.4.7.Velcade

6.4.8.Imbruvica

6.4.9.Ibrance

6.4.10. Zytiga

6.4.11. Alimta

6.4.12. Xtandi

6.4.14. Tarceva

6.4.14. Perjeta

6.4.15. Temodar

6.4.16. Others

6.5. By End-user

6.5.1. Hospitals

6.5.2. Specialty Clinics

6.5.3. Cancer & Radiation Therapy

6.6. By Region

6.6.1. North [Hokkaido and Tohoku]

6.6.2. Central [Kanto and Chubu]

6.6.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]

7. Market Mapping, 2024

7.1. By Application

7.2. By Therapeutics

7.3. By Top Selling Drugs

7.4. By End-user

7.5. By Region

8. Macro Environment and Industry Structure

8.1. Supply Demand Analysis

8.2. Import Export Analysis

8.3. Value Chain Analysis

8.4. PESTEL Analysis

8.4.1. Political Factors

8.4.2. Economic System

8.4.3. Social Implications

8.4.4. Technological Advancements

8.4.5. Environmental Impacts

8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)

8.5. Porter’s Five Forces Analysis

8.5.1. Supplier Power

8.5.2. Buyer Power

8.5.3. Substitution Threat

8.5.4. Threat from New Entrant

8.5.5. Competitive Rivalry

9. Market Dynamics

9.1. Growth Drivers

9.2. Growth Inhibitors (Challenges and Restraints)

10. Regulatory Framework and Innovation

10.1. Clinical Trials

10.2. Patent Landscape

10.3. Regulatory Approvals

10.4. Innovations/Emerging Technologies

11. Key Players Landscape

11.1. Competition Matrix of Top Five Market Leaders

11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2024)

11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)

11.4. SWOT Analysis (For Five Market Players)

11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

14.1. Daiichi Sankyo Company, Ltd.

14.1.1. Company Details

14.1.2. Key Management Personnel

14.1.3. Products & Services

14.1.4. Financials (As reported)

14.1.5. Key Market Focus & Geographical Presence

14.1.6. Recent Developments

14.2. Takeda Pharmaceutical Company Ltd.

14.3. Chugai Pharmaceutical Co., Ltd.

14.4. Astellas Pharma Inc.

14.5. Otsuka Pharmaceutical Co., Ltd.

14.6. Eisai Co., Ltd.

14.7. Shionogi & Co., Ltd.

14.8. Kyowa Kirin Co., Ltd.

14.9. Ono Pharmaceutical Co., Ltd.

14.10. Sumitomo Pharma Co., Ltd.

14.11. Novartis Pharma K.K.

14.12. Bristol-Myers Squibb Company Ltd.

14.14. Janssen Pharmaceutical K.K

14.14. AstraZeneca Pharma Japan Ltd.

14.15. Pfizer Japan Inc.

15. Strategic Recommendations

16. About Us & Disclaimer